WO2007093897A2 - Procédé de préparation d'une composition phytothérapeutique avec goût amer masqué et produit obtenu par ce procédé - Google Patents

Procédé de préparation d'une composition phytothérapeutique avec goût amer masqué et produit obtenu par ce procédé Download PDF

Info

Publication number
WO2007093897A2
WO2007093897A2 PCT/IB2007/000354 IB2007000354W WO2007093897A2 WO 2007093897 A2 WO2007093897 A2 WO 2007093897A2 IB 2007000354 W IB2007000354 W IB 2007000354W WO 2007093897 A2 WO2007093897 A2 WO 2007093897A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
sodium
extract
antioxidant
Prior art date
Application number
PCT/IB2007/000354
Other languages
English (en)
Other versions
WO2007093897A3 (fr
Inventor
Sateesh Kumar Chauhan
Deepak Bahri
Original Assignee
Promed Exports Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promed Exports Private Limited filed Critical Promed Exports Private Limited
Priority to EA200800274A priority Critical patent/EA013243B1/ru
Publication of WO2007093897A2 publication Critical patent/WO2007093897A2/fr
Publication of WO2007093897A3 publication Critical patent/WO2007093897A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • This invention relates to a process for preparation of an herbal composition useful in treatment of liver disorders.
  • the invention also relates to the herbal composition comprising enhanced concentration of bioactive compounds, thus providing a more efficacious product in a form suitable even for children.
  • Andrographis paniculata In the past, the benefits of some herbs such as Andrographis paniculata, Picrorhi ⁇ a kurroa, Phyllanthis niruri, Tinospora cordifolia, Eclipta alba, Solarium nigrum have been recognized as having hepatoprotective properties.
  • the problem has been, however, that the main active herbal constituents i.e. Andrographis paniculata known as king of bitters, Picrorhiza kurroa, Phyllanthius niruri, Tinospora cordifolia, Eclipta alba and Solanum nigrum are characterized by a strong bitter taste, rendering it unpalatable.
  • the principal object of this invention is to provide a process for preparing an herbal composition comprising bitter tasting herbs and wherein the herbal extracts are present in enhanced concentration and simultaneously masking the bitterness.
  • the present invention provides a process for preparing an herbal composition comprising the steps of: (a) preparing an extract of herbs, selected from one or more of Picrorhiza kurroa, Andrographis paniculata, Phyllanthus niruri, Eclipta alba Solanum nigrum, Tinospora cordifolia, Boerhaavia diffusa, Piper longum, Zingiber officinale, Bacopa monneiri ; (b) adding an anti-oxidant to the extract, and optionally boiling the extract; (c) subjecting the extract to filtration and concentrating residual mass obtained into a concentrates; (d) finally formulating the concentrate in a physical form by adding pharmaceutically acceptable carrier or excipient to obtain a herbal composition.
  • Fig. 1 (a) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of hepatitis and gradual improvement in anorexia, indigestion and nausea, the three main symptoms of hepatitis.
  • Fig. 1 (b) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of hepatitis and SGPT, ALP value.
  • Fig. 1 (c) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of hepatitis and Serum bilirubin value.
  • Fig. 2 (a) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of alcoholic hepatitis and gradual improvement in anorexia, indigestion and nausea, the three main symptoms of hepatitis.
  • Fig. 2 (b) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of alcoholic hepatitis and Liver function test.
  • Fig. 2 (c) is a graph which shows result of clinical trails of Set 2 or Set C formulation in form of bar diagram with respect to treatment of alcoholic hepatitis and total Serum bilirubin value.
  • the present invention provides a process for preparing an herbal composition comprising the steps-
  • the herbal composition of the invention comprises;
  • the antioxidants used in the extraction are water soluble antioxidant such as sodium metabisulphite, sodium sulfite, sodium-bisulfite, sodium thiosulfate, ascorbic acid, citric acid etc.
  • the anti-oxidant is metabisulphite as extraction with this antioxidant showed remarkably masked bitter masking in comparison to other antioxidant.
  • the optimized batch (Set-C or Set-2) using sodium metabisulphite as an antioxidant used further for efficacy and analysis used further for efficacy and analysis "purposes as these batches were showing masked bitterness for the herbal composition.
  • the yield of extraction is increased up to 54 % by weight over the traditional method and more than 100 % by weight with respect to bioactive compounds, thus increasing the bioactivity of resultant product.
  • the herbal composition of the present invention is synergistic in nature in that as many pharmaceutical companies either use the sub optimum concentration of given active constituents or use the aqueous distillate of given bitter herbs, which do not contain the active constituents, which are present in the herbs as they are not volatile and hence the bio efficacy of such preparation was always questionable whereas present herbal composition comprises bitter herbs such as Picrorhiza kurroa, Andrographis paniculata, Phyllanthus niruri, Eclipta alba Solanum nigrum, Tinospora cordifolia, Boerhaavia diffusa, Piper longum, Zingiber officinale, Bacopa monneiri to yield surprisingly significant enhanced bioactive compounds and also surprisingly masking their unpleasant bitter taste rendering it suitable even for children.
  • bitter herbs such as Picrorhiza kurroa, Andrographis paniculata, Phyllanthus niruri, Eclipta alba Solanum nigrum, Tinospor
  • composition of the present invention is a synergistic composition and not a mere admixture
  • the resultant herbal extract with sodium metabisulphite as anti-oxidants provides almost nil to very mild bitter taste, and may be easily formulated in to palatable formulation.
  • the base may contain pharmaceutically acceptable excepients such as sweetening agents eg. Sucrose, sorbitol solution, glycerol, preservative such as methyl paraben, propyl paraben or higher salts there of, sorbic acids or salts thereof, benzoic acids or salts there of, buffering agents such as citrate, ascorbate, phosphate or other suitable buffer, and suitable coloring and flavoring agents.
  • the herbal composition prepared by the process of the present invention is in the dosage form of tablet, capsule, powder, granules or syrup.
  • the excipient of the herbal composition are selected from a group comprising diluents, binders, disintegrants, lubricants, glidants, sweetening agent, flavouring agent, solubilizers, suspending agents, preservatives, antibacterial agents, antioxidants, buffers and stabilizer.
  • the resultant dry powder extract obtained using given process can be blended with suitable pharmaceutical acceptable excepients such as diluents such as micro crystalline cellulose, lactose, calcium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium carbonate etc, disintegrating agents such as natural gums, different derivatives of cellulose, starch, sodium starch glycolate, sodium lauryl sulphate, etc, lubricants and glidents such as colloidal silicon dioxide, talc, stearic acid and magnesium stearate etc.
  • suitable pharmaceutical acceptable excepients such as diluents such as micro crystalline cellulose, lactose, calcium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium carbonate etc
  • disintegrating agents such as natural gums, different derivatives of cellulose, starch, sodium starch glycolate, sodium lauryl sulphate, etc
  • lubricants and glidents such as colloidal silicon dioxide, talc, stearic acid and magnesium ste
  • the active ingredient in the herbal composition prepared from the filtered and concentrated extract may be present upto 70% by weight
  • part and parts mean “part by weight” and “parts by weight”, respectively, unless otherwise specified.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. sodium metabisulphite (Table- 1 or Table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight by weight and propyl paraben sodium at 0.02 % by weight by weight were added to it and the liquid left overnight. Next day clear liquid decanted and sample used for calculating the content of extractible matter from the herbs, bitterness and for HPTLC analysis.
  • Table 1- shows herbal hepatoprotective composition containing different amount of sodium metabisulphite as anti-oxidant during extraction process.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. sodium bisulfite (table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight by weight and propyl paraben sodium at ⁇ .02 % by weight were added to it and the liquid left overnight.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. sodium thiosulfate (Table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight and propyl paraben sodium at 0.02 % by weight were added to it and the liquid left overnight.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. sodium sulfite (Table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight and propyl paraben sodium at 0.02 % by weight were added to it and the liquid left overnight.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. ascorbic acid (Table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight and propyl paraben sodium at 0.02 % by weight were added to it and the liquid left overnight. Next day clear liquid decanted and sample used for calculating the content of extractible matter from the herbs, bitterness and for HPTLC analysis.
  • the composite herbal formulation containing following herbs were weighed, coarsely ground and extracted with and without antioxidant ie. citric acid (Table-2) with 8 times of demineralised water by boiling the contents over heating mantle for 5 minutes.
  • the respective samples were filtered through two-fold muslin cloth, volume made up to 200 ml with demineralised water and methyl paraben sodium at 0.2 % by weight and propyl paraben sodium at 0.02 % by weight were added to it and the liquid left overnight. Next day clear liquid decanted and sample used for calculating the content of extractible matter from the herbs, bitterness and for HPTLC analysis.
  • Table 2- shows herbal hepatoprotective composition containing different anti oxidants during extraction process.
  • the concentrate as obtained from examples 1 to 6 was formulated into palatable syrup formulation by adding to a base containing sucrose, sorbitol solution, glycerol, preservative such as methyl paraben and propyl paraben with suitable buffering agents such as citrate, ascorbate, phosphate or other suitable buffer, and suitable colouring agent and flavouring agents.
  • suitable buffering agents such as citrate, ascorbate, phosphate or other suitable buffer, and suitable colouring agent and flavouring agents.
  • the concentrate as obtained from examples 1-6 is converted into dry powder extract by using vaccum drier.
  • the resultant dry powder extract is blended with suitable pharmaceutical acceptable excepients such as diluents such as micro crystalline cellulose, lactose, calcium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium carbonate etc, disintegrating agents such as natural gums, different derivatives of cellulose, starch, sodium starch glycolate, sodium lauryl sulphate, etc, lubricants and glidents such as colloidal silicon dioxide, talc, stearic acid, magnesium stearate etc.
  • suitable pharmaceutical acceptable excepients such as diluents such as micro crystalline cellulose, lactose, calcium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium carbonate etc
  • disintegrating agents such as natural gums, different derivatives of cellulose, starch, sodium starch glycolate, sodium lauryl sulphate, etc
  • lubricants and glidents
  • the concentrate as obtained from examples 1-6 is converted into dry powder extract by using vaccum drier.
  • the resultant dry powder extract is blended with suitable pharmaceutical acceptable excepients such as diluents such as bentonite, lactose, calcium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium carbonate, mannitol, magnesium carbonate etc, lubricants and glidents such as colloidal silicon dioxide, talc, stearic acid, magnesium stearate etc.
  • the resultant powder mixture is then filled into capsules of desirable size ranges such as capsule size of 0 to 5 which can fill upto 0.6gm to 0.12 gm.
  • Table 3- shows extractive values of different samples of herbal hepatoprotective composition taking different anti-oxidant during extraction process.
  • Table-4 shows evaluation of bitterness in different samples of herbal hepatoprotective composition with sodium metabisulphite as anti-oxidant during extraction process.
  • micro crystalline cellulose dried starch, talc, sodium lauryl sulphate, cross Carmellose sodium, sodium starch glycolate, and magnesium stearate was added and mass was mixed thoroughly. This mass was passed 0 through sieve No. 16 followed by sieve of mesh no. 20 to get the granules of desired size. Compression was performed on a multi station tabletting machine with 15 mm capsule shaped elongated punches to prepare tablets of weight 550 mg.
  • Powdered extract was formulated into palatable syrup by adding to a base containing sucrose, glycerol, preservative such as methyl paraben sodium and propyl paraben sodium with suitable buffering agents such as citrate Buffer and caramel as a colouring agent and mint as a flavouring agents.
  • Table 7- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of hepatitis and gradual improvement in anorexia, indigestion and nausea, the three main symptoms of hepatitis.
  • the results shows percentage of patients showing gradual improvement in anorexia, indigestion and nausea, which are the three main symptoms of hepatitis on 0, 7 th and 15 th day after taking herbal composition. Symptoms gradually come down from 7 th day of 33% by weight, 20% by weight and 20% by weight to lower 13.5% by weight, 0% by weight and 0% by weight for anorexia, indigestion and nausea respectively. Anorexia was found to be reduced significantly from 100% by weight to 13.5% by weight on 15 th day of observation whereas indigestion and nausea was found to be completely absent from patients on 15 l day of observation. Also shown in figure 1 (a) wherein grey bar shows Day 0, dark grey bar shows Day 7 and white bar shows Day 15.
  • Table 8- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of hepatitis and SGPT, ALP value.
  • Serum bilirubin was found to be 5.94 mg/ml, 6.15 mg/ml and 3.14 mg/ml after 1 st , 2 nd and 3 rd visit respectively whereas direct bilirubin was found to be 4.65 mg/ml, 4.87 mg/ml and 2.52 mg/ml after 1 st , 2 nd and 3 rd visit respectively and indirect bilirubin was found to be 1.36 mg/ml, 1.46 mg/ml and 1.08 mg/ml after 1 st , 2 nd and 3 rd visit respectively.
  • Serum bilirubin was found to be reduced significantly from 5.94 mg/ml to 3.14 mg/ml on 3 rd visit whereas direct bilirubin was found to be reduced significantly from 4.65 mg/ml to 2.52 mg/ml on 3 rd visit and indirect bilirubin was found to be reduced significantly from 1.36 mg/ml to 1.08 mg/ml on 3 rd visit. Also shown in figure 1 (b) wherein grey bar shows 1 st visit, dark grey bar shows 2 nd visit and white bar shows 3 rd visit.
  • Table 9- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of hepatitis and Serum bilirubin value.
  • SGPT and ALP value in IU/L after 1 st , 2 nd and 3 rd visit.
  • SGPT value was found to be 375.9 IU/L, 211.9 IU/L and 97.33 IU/L after 1 st , 2 nd and 3 rd visit respectively whereas ALP value was found to be 373.9 IU/L, 347.7 IU/L and 280.67 IU/L after 1 st , 2 nd and 3 rd visit respectively.
  • SGPT was reduced significantly from 375 IU/L to 97.33 IU/L on 3 rd visit whereas ALP was reduced significantly from 375 IU/L to 97.33 IU/L on 3 rd visit.
  • figure 1 (c) wherein grey bar shows 1 st visit, dark grey bar shows 2 nd visit and white bar shows 3 rd visit.
  • Table 10- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of alcoholic hepatitis and gradual improvement in anorexia, indigestion and nausea, the three main symptoms of hepatitis.
  • the results shows mean grade of patients which shows gradual improvement in anorexia, indigestion and nausea, which are the three main symptoms of hepatitis on 0, 2, 4, 8 and 12 weeks after taking herbal composition .
  • Tiredness was found to be 4.3, 3.53, 2.88, 2.44 and 1.86 in mean grade after 0, 2, 4, 8 and 12 weeks respectively whereas weakness was found to be 4.36, 3.64, 2.94, 2.33 and 1.73 in mean grade after 0, 2, 4, 8 and 12 weeks respectively and anorexia was found to be 4.25, 3,98, 2.78, 2.2 and 1.78 in mean grade after 0, 2, 4, 8 and 12 weeks respectively.
  • Tiredness was reduced significantly from mean grade of 4.3 to 1.86 after 12 week whereas weakness was reduced significantly from mean grade of 4.36 to 1.73 after 12 week and anorexia was reduced significantly from mean grade of 4.25 to 1.78 after 12 week. Also shown in figure 2(a) wherein grey bar shows Week 0, dark grey bar shows Week 2, white bar shows Week 4, yellow bar shows Week 8 and Black bar shows week 12.
  • Table 11- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of alcoholic hepatitis and Liver function test.
  • liver function test in terms of IU/L on 0, 4, 8 and 12 weeks after taking herbal composition.
  • ALT was found to be 148.66 IU/L, 78.22 IU/L, 52.75 IU/L and 48.53 IU/L after 0, 4, 8 and 12 weeks respectively whereas AST was found to be 162.78 IU/L, 82.25 IU/L, 62.38 IU/L and 48.00 IU/L after 0, 4, 8 and 12 weeks respectively and
  • ALP was found to be 181.38 IU/L, 166.47 IU/L, 146.25 IU/L and 121.47 IU/L after 0, 4, 8 and 12 weeks respectively.
  • ALT value was decreased significantly after 12 weeks from 148.66 to 48.53 mg/ml whereas AST value was decreased significantly afterl2 weeks from 162.78 to 48 and ALP value was decreased significantly after 12 weeks from 181.38 to 121.47. Also shown in figure 2(b) wherein grey bar shows Week 0, dark grey bar shows Week 4, white bar shows Week 8 and yellow bar shows Week 12.
  • Table 12- shows result of clinical trails of Set 2 or Set C formulation with respect to treatment of alcoholic hepatitis and total Serum bilirubin value.
  • the result shows total serum bilirubin value in mg/ml on 0, 2, 3 and 4 weeks after taking herbal composition.
  • Total serum bilirubin was found to be 2.98 mg/ml, 1.6 mg/ml, 1.34 mg/ml and 1.1 mg/ml after 0, 2, 3 and 4 weeks respectively.
  • Total serum bilirubin value was decreased significantly after 4 weeks from 2.98 mg/ml to 1.1 mg/ml. Also shown in figure 2(c) wherein grey bar shows Week 0, dark grey bar shows Week 2, white bar shows Week 3 and yellow bar shows Week 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé permettant d'utiliser des herbes médicinales ayant un goût amer dans une composition phytothérapeutique possédant des propriétés hépatoprotectrices. La composition comprend une ou plusieurs herbes parmi Picrorhiza kurroa, Andrographis paniculata, Phyllanthus niruri, Eclipta alba Solanum nigrum, Tinospora cordifolia, Boerhaavia diffusa, Piper longum, Zingiber officinale, Bacopa monneiri et elle est utilisable même en pédiatrie.
PCT/IB2007/000354 2006-02-16 2007-02-15 Procédé de préparation d'une composition phytothérapeutique avec goût amer masqué et produit obtenu par ce procédé WO2007093897A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200800274A EA013243B1 (ru) 2006-02-16 2007-02-15 Способ приготовления композиции из лекарственных трав с маскированным горьким вкусом и композиция, полученная по этому способу

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN376/DEL/2006 2006-02-16
IN376DE2006 2006-02-16

Publications (2)

Publication Number Publication Date
WO2007093897A2 true WO2007093897A2 (fr) 2007-08-23
WO2007093897A3 WO2007093897A3 (fr) 2007-11-01

Family

ID=38371881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000354 WO2007093897A2 (fr) 2006-02-16 2007-02-15 Procédé de préparation d'une composition phytothérapeutique avec goût amer masqué et produit obtenu par ce procédé

Country Status (2)

Country Link
EA (1) EA013243B1 (fr)
WO (1) WO2007093897A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119294A3 (fr) * 2009-04-16 2010-12-09 Ron Fields Nutrition Composition
WO2012056476A1 (fr) * 2010-10-25 2012-05-03 Manu Chaudhary Formulation détoxifiante à base de plantes médicinales
WO2013042131A1 (fr) 2011-09-23 2013-03-28 M KUMAR, Anil Procédé de préparation d'une préparation synergique d'herbes officinales à base d'extraits de picrorhiza kurroa et de glycyrrhiza glabra possédant des vertus médicinales
US11576941B2 (en) * 2016-06-21 2023-02-14 Laila Nutraceuticals Taste masking formulation for bitter natural compounds
WO2023039105A1 (fr) * 2021-09-08 2023-03-16 Karallief, Inc. Compositions thérapeutiques à base de plantes pour améliorer la santé du foie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170326A1 (en) * 2001-12-13 2003-09-11 Council Of Scientific And Industrial Research Bioavailability enchancing activity of Zingiber officinale Linn and its extracts/fractions thereof
WO2005097149A2 (fr) * 2004-04-09 2005-10-20 Nicholas Piramal India Limited Extrait d'herbes pour troubles renaux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170326A1 (en) * 2001-12-13 2003-09-11 Council Of Scientific And Industrial Research Bioavailability enchancing activity of Zingiber officinale Linn and its extracts/fractions thereof
WO2005097149A2 (fr) * 2004-04-09 2005-10-20 Nicholas Piramal India Limited Extrait d'herbes pour troubles renaux

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119294A3 (fr) * 2009-04-16 2010-12-09 Ron Fields Nutrition Composition
WO2012056476A1 (fr) * 2010-10-25 2012-05-03 Manu Chaudhary Formulation détoxifiante à base de plantes médicinales
US9233133B2 (en) 2010-10-25 2016-01-12 Manu Chaudhary Detoxifier herbal formulation
WO2013042131A1 (fr) 2011-09-23 2013-03-28 M KUMAR, Anil Procédé de préparation d'une préparation synergique d'herbes officinales à base d'extraits de picrorhiza kurroa et de glycyrrhiza glabra possédant des vertus médicinales
US11576941B2 (en) * 2016-06-21 2023-02-14 Laila Nutraceuticals Taste masking formulation for bitter natural compounds
WO2023039105A1 (fr) * 2021-09-08 2023-03-16 Karallief, Inc. Compositions thérapeutiques à base de plantes pour améliorer la santé du foie

Also Published As

Publication number Publication date
EA013243B1 (ru) 2010-04-30
WO2007093897A3 (fr) 2007-11-01
EA200800274A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
US8541383B2 (en) Synergistic phytochemical composition for the treatment of obesity
US6153198A (en) Withania somnifera composition
US7842315B2 (en) Compositions for treating liver fibrosis or cirrhosis
KR100586813B1 (ko) 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는 치료용 건강식품
JP6031662B2 (ja) 認知機能低下改善用組成物
KR20020041639A (ko) 천연 생약제 추출물을 포함하는 숙취해소용 조성물 및이를 유효성분으로 함유하는 건강보조식품
WO2007093897A2 (fr) Procédé de préparation d'une composition phytothérapeutique avec goût amer masqué et produit obtenu par ce procédé
KR100896453B1 (ko) 페라고늄 시도이데스 시럽
KR101295125B1 (ko) 항산화 기능성 조성물 및 이를 함유하는 기능성 식품
ITTO20010283A1 (it) Composizione di erbe e procedimento di fabbricazione di tale composizione per il trattamento di disturbi ginecologici.
EP2512444B1 (fr) Melanges de plantes dans une teinture-mere spagyrique contre la toux seche chez les bebes
KR20110139548A (ko) 가시오가피를 함유한 숙취 해소 및 간기능 개선용 생약조성물 및 그 제조방법
KR20190132420A (ko) 약초 조성물
KR102002298B1 (ko) 생약 추출물을 포함하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
US6355279B1 (en) Composition improving lipid metabolism
CN1326539C (zh) 炎宁胶囊及其制备工艺
US20230119836A1 (en) Chinese herbal medicine composition for relieving hearing loss and preparation method and use thereof
KR100443116B1 (ko) 항비만 및 항콜레스테롤 효과를 나타내는 보이차 조성물
KR20210116929A (ko) 숙취해소제의 제조 방법 및 이에 의해 제조된 숙취해소제
US7172772B2 (en) Herbal composition for gastrointestinal disorders
KR100372022B1 (ko) 간경화의 예방 및 치료용 의약조성물
CN101518642B (zh) 液体内服剂
WO2024023854A1 (fr) Composition anti-inflammatoire à base d'herbes
CN111759901B (zh) 一种治疗儿童功能性腹痛的中药组合物及其制备方法
CN114711313A (zh) 一种茶叶提取物组合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200800274

Country of ref document: EA

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07705590

Country of ref document: EP

Kind code of ref document: A2